Additionally, lack of c-Myc amplification in supratentorial PNET tumor tissue and in the PFSK-1 cell line may be a contributing factor to sensitivity to RHPS4 as patients with other PNET tumors which exhibit overexpression or amplification of c-Myc, have an extremely poor prognosis with poor response to chemotherapy [52], [53]. The gene discussed is MYC; the disease is primitive neuroectodermal tumor.